

Estimate change	↑
TP change	↑
Rating change	↔

CMP: INR2,380 TP: INR2,520 (+6%) Neutral

Broad-based growth drives earnings; strong finish in FY26

Earnings to be constrained for FY27/FY28; reiterate Neutral

Bloomberg	LPC IN
Equity Shares (m)	457
M.Cap.(INRb)/(USD\$b)	1087.9 / 11.5
52-Week Range (INR)	2494 / 1837
1, 6, 12 Rel. Per (%)	3/26/19
12M Avg Val (INR M)	2086

Financials & Valuations (INR b)

Y/E MARCH	FY26	FY27E	FY28E
Sales	279.6	307.5	334.4
EBITDA	81.6	78.4	81.6
Adj. PAT	53.3	50.2	52.0
EBIT Margin (%)	24.6	21.0	20.0
Cons. Adj. EPS (INR)	116.5	109.8	113.7
EPS Gr. (%)	62.9	-5.8	3.6
BV/Sh. (INR)	491.0	616.6	727.4

Ratios

Net D:E	0.0	-0.1	-0.2
RoE (%)	26.9	19.8	16.9
RoCE (%)	21.7	17.0	15.3
Payout (%)	2.5	2.6	2.6

Valuations

P/E (x)	20.4	21.7	20.9
EV/EBITDA (x)	13.4	13.5	12.4
Div. Yield (%)	0.1	0.1	0.1
FCF Yield (%)	4.2	2.9	5.2
EV/Sales (x)	3.9	3.5	3.0

Shareholding pattern (%)

As On	Mar-26	Dec-25	Mar-25
Promoter	46.9	46.9	46.9
DII	25.3	25.6	25.4
FII	21.7	21.5	21.5
Others	6.1	6.0	6.2

FII includes depository receipts

- Lupin (LPC) delivered another quarter of strong performance with a 7%/11%/10% beat on revenue/EBITDA/PAT for the quarter. Increased traction in niche products in the US, coupled with broad-based growth across key geographies, led to the growth momentum in 4QFY26 as well.
- Effectively, FY26 would be the third straight year of strong growth in earnings (380%, 73%, and 63% YoY for FY24, FY25, and FY26, respectively).
- The US surpassed USD1.3b in sales, the highest annual sales ever, due to limited competition products like g-Tolvaptan, g-Mirabegron, and g-Risperdal Consta.
- LPC outperformed the domestic formulation prescription (Rx) market by 1.1x, with cardiology, respiratory, and pain growing much higher than the industry.
- LPC exhibited strong execution in LATAM as well as ROW markets in FY26.
- We raise our earnings estimate by 4%/3% for FY27/FY28, factoring in 1) better-than-industry growth in Rx and emerging markets, 2) the addition of sales from Visufarma, and 3) scale-up of the biosimilar business. We value LPC at 22x 12M forward earnings to arrive at our TP of INR2,520.
- While LPC ended FY26 on a strong note, we estimate earnings to remain stable over FY26-28 due to competition expected in certain niche products in the US market. The current valuation provides limited upside. **Hence, we reiterate our Neutral rating on the stock.**

LPC ends FY26 on a strong note with healthy margin-led growth

- LPC's 4QFY26 revenue grew 31.9% YoY to INR74.7b. (our est. INR70.1b).
- Gross Margin (GM) expanded 500bp YoY to 75.2%.
- EBITDA margin expanded 620bp YoY to 29% (our est: 27.9%), largely due to better GM.
- As a result, EBITDA grew 68% YoY to INR21.7b (vs our est: INR19.6b).
- Adj. PAT grew 85.7% YoY to INR13.9b (our est: INR12.7b).
- For FY26, Revenue/EBITDA/PAT grew 24%/51%/70% YoY.

Broad-based growth across geographies

- US sales grew 57% YoY to INR34b (up 48% YoY in CC to USD371m; 46% of sales).
- Domestic formulation (DF) sales grew 11.5% YoY to INR19.1b (26% of sales).
- Other developed market sales grew 7.1% YoY to INR8.5b (11% of sales).
- Emerging market sales grew 49.2% YoY to INR 9.9b (13% of sales).
- API sales increased 7.6% YoY to INR2.5b (4% of sales).
- LPC received three ANDA approvals and launched three products in 4QFY26.
- Launched three brands across therapies in India during the quarter.
- R&D for the 4Q/FY26 was INR5.9b/INR20.6b (8%/7.5%).

Tushar Manudhane - Research Analyst (Tushar.Manudhane@MotilalOswal.com)

Research Analyst: Vipul Mehta (vipul.mehta@motilalosal.com) | **Eshita Jain** (Eshita Jain @MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilalosal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

Highlights from the management commentary

- Management guided a high single-digit revenue growth with an EBITDA margin of 25% in FY27.
- Management indicated that the US business is expected to sustain annual revenues above USD1b, despite increased competition in products such as Mirabegron and Tolvaptan.
- For FY27/FY28, LPC indicated an expectation of high single-digit to low double-digit revenue erosion, given competitive intensity across the portfolio.
- Over the next three years, management expects to launch 50+ products in the US, including 10 exclusive/first-to-file opportunities, multiple biosimilars, and 2-3 505(b)(2) products. Initial biosimilar launches in the US are expected from FY27 onwards.
- The domestic formulations (DF; Rx) business is expected to continue outperforming the IPM by 1.2x-1.3x.
- Chronic therapies' contribution to the Rx India business was 66% in FY26 vs. 64% in FY25, with management targeting 70% contribution over the next five years.
- DF-Rx business reported volume growth of 6.4% YoY in FY26 versus IPM growth of 2.6%. Respiratory and cardiac segments grew 2.5x and 1.3x versus industry growth in their respective categories.
- The company launched 15 products in FY26 and plans to launch another 20 in FY27 in India.

Consolidated - Quarterly Earnings Model

Y/E March	FY25				FY26				FY25	FY26	FY26E	% Var
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q				
INRm												
Net Sales	56,003	55,427	56,927	56,671	62,684	70,475	71,675	74,747	2,25,028	2,79,580	70,084	6.7
YoY Change (%)	21.5	10.0	9.5	14.2	11.9	27.1	25.9	31.9	13.6	24.2	23.7	
Total Expenditure	42,389	43,059	43,162	43,750	46,269	49,099	49,580	53,036	1,72,361	1,97,984	50,531	
EBITDA	13,614	12,368	13,765	12,921	16,415	21,376	22,095	21,711	52,668	81,597	19,554	11.0
YoY Change (%)	109.0	34.0	34.7	29.6	20.6	72.8	60.5	68.0	46.6	54.9	51.3	
Margins (%)	24.3	22.3	24.2	22.8	26.2	30.3	30.8	29.0	23.4	29.2	27.9	
Depreciation	2,477	2,569	2,715	3,932	2,990	3,168	3,130	3,589	11,693	12,876	3,559	
EBIT	11,137	9,799	11,050	8,989	13,425	18,208	18,965	18,122	40,975	68,721	15,994	
YoY Change (%)	167.3	45.1	44.5	21.3	20.5	85.8	71.6	101.6	57.7	67.7	77.9	
Margins (%)	19.9	17.7	19.4	15.9	21.4	25.8	26.5	24.2	18.2	24.6	22.8	
Interest	680	709	669	891	918	1,076	1,150	1,202	2,949	3,851	224	
Other Income	678	423	537	570	790	900	1,147	1,407	2,207	3,450	613	
EO Exp/(Inc)	1,204	-1,036	956	-291	-859	-2,037	3,742	-953	834	-106	0	
PBT	9,930	10,549	9,963	8,958	14,156	20,070	15,220	19,280	39,401	68,427	16,383	
Tax	1,875	1,954	2,124	1,135	1,941	5,221	3,415	4,593	7,087	15,171	3,637	
Rate (%)	18.9	18.5	21.3	12.7	13.7	26.0	22.4	23.8	18.0	22.2	22.2	
Minority Interest	-42	-69	-37	-99	-24	-69	-50	-83	-246	-226	-72	
Reported PAT	8,013	8,526	7,802	7,726	12,191	14,779	11,756	14,604	32,067	53,329	12,675	
Adj PAT	8,990	7,682	8,554	7,472	11,450	13,272	14,658	13,879	32,698	53,258	12,675	9.5
YoY Change (%)	214.9	55.5	42.6	47.0	27.4	72.8	71.4	85.7	73.2	62.9	69.6	
Margins (%)	16.1	13.9	15.0	13.2	18.3	18.8	20.5	18.6	14.5	19.0	18.1	
EPS	20	17	19	16	25	29	32	30	72	117	28	9.5

Key Performance Indicators (Consolidated)


Y/E March	FY25				FY26				FY25	FY26
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q		
INRm										
Domestic formulations	19,381	20,096	19,305	17,113	20,894	20,777	20,387	19,082	75,895	81,140
YoY Change (%)	18.3	18.8	11.9	6.9	7.8	3.4	5.6	11.5	14.0	6.9
US formulations	19,337	18,753	20,221	21,666	24,041	27,624	31,132	33,987	79,977	1,16,784
YoY Change (%)	21.6	0.5	7.1	14.0	24.3	47.3	54.0	56.9	10.4	46.0
Other developed markets	6600	6824	7328	6915	7748	8117	8121	8453	27667	32439
YoY Change (%)	65.5	43.4	41.7	30.0	17.4	18.9	10.8	22.2	43.8	17.2
Emerging markets	6203	6353	6441	6660	6524	9228	9170	9906	25657	25978
YoY Change (%)	8.4	(0.2)	(4.1)	10.4	5.2	45.3	42.4	48.7	3.3	1.3
API	3,622	2,944	2,891	2,316	2,431	2,568	2,195	2,491	11,773	9,685
YoY Change (%)	7.4	9.7	4.0	(10.3)	(32.9)	(12.8)	(24.1)	7.6	3.1	(17.7)
Cost Break-up										
RM Cost (% of Sales)	31.2	30.5	30.2	29.8	28.3	25.9	26.2	24.8	30.8	26.7
Staff Cost (% of Sales)	17.3	18.2	17.3	17.7	17.3	15.7	16.0	16.6	17.9	16.6
R&D Expenses(% of Sales)	6.2	8.1	7.6	9.4	7.7	7.2	7.5	7.9	8.0	7.7
Other Cost (% of Sales)	21.0	20.9	20.7	20.3	20.5	20.9	19.6	21.7	21.0	21.0
Gross Margins(%)	68.8	69.5	69.8	70.2	71.7	74.1	73.8	75.2	69.2	73.3
EBITDA Margins(%)	24.3	22.3	24.2	22.8	26.2	30.3	30.8	29.0	23.4	29.2
EBIT Margins(%)	19.9	17.7	19.4	15.9	21.4	25.8	26.5	24.2	18.2	24.6

Highlights from the management commentary

- During the quarter, the company launched Semaglutide injection under the brand “SemaNext”. Oral Semaglutide launch is expected later this financial year.
- Emerging markets strategy is focused on diabetes and metabolic therapies, with planned launches of Empagliflozin in Brazil and South Africa and Semaglutide in South Africa later this year.
- Management highlighted India, South Africa, and Brazil as key markets for the Semaglutide opportunity within emerging markets.
- Semaglutide has already been launched in India, while launches in South Africa and Brazil are expected during FY27. For Canada, the company expects to file during FY27, with launch anticipated next year through partnerships.
- Brazil reported 113% YoY growth in CC, driven by the commercialization of Dapagliflozin.
- Management indicated that the VISUfarma acquisition expands the company’s presence in Europe beyond the UK, Germany, and France into Italy and Spain. VISUfarma’s ophthalmology portfolio is expected to continue delivering double-digit growth in Europe. Management also highlighted the potential to commercialize VISUfarma’s portfolio in Latin America and Southeast Asia, along with evaluating opportunities in select developed markets. Management indicated that VISUfarma revenue could cross EUR100m over the next 2-3 years.
- LPC expects the FY27 effective tax rate (ETR) to be 25-26% due to the phased withdrawal of tax incentives at certain domestic manufacturing facilities.
- LPC indicated that some PLI benefits are expected to continue in FY27, though at lower levels versus earlier periods.
- Capex for the 4Q/FY26 was INR3.1b/10.6b.


Key exhibits

Exhibit 1: US sales increased 57% YoY in 4QFY26



Source: MOFSL, Company

Exhibit 2: DF sales up 11.5% YoY in 4QFY26



Source: MOFSL, Company

Diversified global franchise strengthens long-term growth visibility

US – Competition in key products may normalize growth trajectory

- US business delivered a strong 40% YoY growth to USD1.3bn in FY26, driven by key products including Tolvaptan, Mirabegron, and complex injectable products such as generic Risperdal Consta.
- Base business growth remained healthy, with volume growth offsetting low-single-digit price erosion and additional competition in select products.
- The company launched 15 products and filed 11 products during FY26, while continuing to strengthen its complex generics and specialty portfolio.
- Near-term pipeline catalysts include Pegfilgrastim, Ranibizumab, Saxenda, Revecti, and respiratory products, alongside continued focus on 505(b)(2) opportunities.
- The company continues to invest meaningfully in R&D (7.5% of sales in FY26) with over 50 active pipeline products focused on respiratory, injectables, and specialty platforms.
- FY27 is likely to witness additional competition in key products such as Tolvaptan and Mirabegron, which may impact growth and profitability versus FY26 peak levels.
- Over FY26-28E, we expect the US business to deliver a CAGR of 5%, supported by continued new product launches and scale-up in complex products; however, rising competition in key products is likely to normalize growth from the elevated FY26 base.

DF - Chronic-led strategy and differentiated launches support sustained outperformance

- DF business grew 7.1% YoY to INR81.1bn in FY26, while the core prescription business delivered 10.6% growth, outperforming IPM growth of 9.9%.
- Growth was supported by strong traction in key chronic therapies, with cardiology and respiratory segments outperforming category growth by 1.3x and 1.7x, respectively.
- Chronic therapies' contribution increased to 66% of India sales in FY26 vs. 64% in FY25, with management targeting ~70% contribution over the next five years.

- The India business continued to witness healthy volume-led growth (+6.4% vs IPM volume growth of 2.6%), indicating strong prescription traction and field execution.
- The company strengthened its diabetes and metabolic franchise with the launch of generic Semaglutide (Semanext), where management indicated an encouraging initial response and top-3 market positioning among branded generics.
- LPC plans to launch ~20 products in FY27, supported by a pipeline of 80+ products across in-house and in-licensed opportunities.
- Expansion of the domestic field force to ~12,000 representatives and improving doctor engagement continue to support prescription growth and market penetration.
- A lower share of in-licensed products (~6% of the portfolio vs. 12% last year) aided profitability improvement in the India business during FY26.
- Over FY26-28E, we expect DF business to deliver a CAGR of 10%, driven by chronic therapy expansion, differentiated launches in diabetes/metabolic therapies, improved field force productivity, and continued outperformance versus IPM growth.


Other - VISUfarma acquisition and strong EM momentum expand global growth runway

- Other Developed Markets (Europe, Canada, and Australia) grew 13.3% YoY to INR32.4b in FY26, driven by steady traction across key markets.
- Europe crossed the USD200m revenue milestone during FY26, supported by healthy double-digit growth and increasing scale in the region.
- The acquisition of VISUfarma marks a strategic step-up in Lupin's specialty and ophthalmology presence across Europe, particularly in Italy and Spain, where the company previously had limited presence.
- Multiple synergy opportunities through VISUfarma, including cross-selling of respiratory, biosimilar, and ophthalmology products, are expected across European and select emerging markets.
- VISUfarma also strengthens LPC's specialty capabilities with an established commercial infrastructure and a differentiated ophthalmology portfolio, which management expects to sustain double-digit growth.
- EM (LATAM, South Africa, Philippines, and RoW) business delivered a robust 35.2% YoY growth to INR34.8b in FY26, led by strong recovery in Brazil and continued momentum in South Africa and the Philippines.
- Brazil emerged as a key growth driver with strong traction in the diabetes/metabolic portfolio, particularly Dapagliflozin, while launches of Empagliflozin and Semaglutide are expected to further strengthen presence in the segment.
- Over FY26-28E, we expect other developed markets and emerging markets to deliver double-digit growth, supported by VISUfarma integration, expansion in ophthalmology and biosimilars, and continued momentum in diabetes/metabolic therapies across key emerging markets.

Reiterate Neutral

- We raise our earnings estimate by 4%/3% for FY27/FY28, factoring in 1) better-than-industry growth in Rx and emerging markets, 2) the addition of sales from Visufarma, and 3) scale-up of the biosimilar business. We value LPC at 22x 12M forward earnings to arrive at our TP of INR2,520.
- While LPC ended FY26 on a strong note, we estimate earnings to remain stable over FY26-28 due to competition expected in certain niche products in the US market. The current valuation provides limited upside. **Hence, we reiterate our Neutral rating on the stock.**

Exhibit 3: P/E chart



Story in charts

Exhibit 4: Revenue mix in 4QFY26




Exhibit 5: Expect a 9.8% sales CAGR over FY25-27




Exhibit 6: R&D spending to inch up going forward




Exhibit 7: EBITDA margin to dip over FY26-28




Exhibit 8: Expect EPS to remain stable over FY26-28





Exhibit 9: 430 cumulative ANDAs filed



Source: MOFSL, Company,

Financials and valuations

Income Statement							(INR m)
Y/E March	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Net Sales	1,60,321	1,66,417	1,98,054	2,25,029	2,79,580	3,07,527	3,34,425
Change (%)	6.2	3.8	19.0	13.6	24.2	10.0	8.7
EBITDA	19,968	17,582	35,932	52,668	81,596	78,419	81,600
Margin (%)	12.5	10.6	18.1	23.4	29.2	25.5	24.4
Depreciation	8,220	8,807	9,956	11,693	12,876	13,909	14,559
EBIT	11,748	8,775	25,977	40,975	68,720	64,511	67,041
Int. and Finance Charges	1,428	2,743	3,116	2,949	3,851	3,925	3,820
Other Income - Rec.	1,504	757	1,218	2,207	3,450	3,230	3,400
PBT before EO item	11,824	6,790	24,079	40,234	68,319	63,816	66,620
EO Expense/(Income)	25,550	-375	-147	834	-106	0	0
PBT after EO item	-13,726	7,165	24,227	39,400	68,425	63,816	66,620
Tax	1,372	2,688	4,867	7,087	15,171	13,401	14,323
Tax Rate (%)	-10.0	37.5	20.1	18.0	22.2	21.0	21.5
Less: Minority Interest	-183	-176	-211	-246	-226	-220	-310
Reported PAT	-15,280	4,301	19,149	32,066	53,028	50,195	51,987
PAT Adj for EO items	8,699	3,915	18,875	32,698	53,258	50,195	51,987
Change (%)	-26.2	-55.0	382.1	73.2	62.9	-5.8	3.6
Margin (%)	5.4	2.4	9.5	14.5	19.0	16.3	15.5

Consolidated Balance Sheet

Y/E March	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
Equity Share Capital	909	910	909	913	914	914	914
Total Reserves	1,20,624	1,23,695	1,41,992	1,71,122	2,23,568	2,80,993	3,31,651
Net Worth	1,21,533	1,24,605	1,42,901	1,72,035	2,24,483	2,81,908	3,32,565
Minority Interest	687	783	831	909	651	871	1,181
Deferred liabilities	711	738	-567	-6,053	-6,137	-3,460	-3,460
Secured Loan	6,147	4,153	3,115	20,820	21,908	19,408	16,408
Unsecured Loan	37,023	42,165	26,699	34,173	44,779	38,668	34,668
Total Loans	43,170	46,318	29,814	54,993	66,687	58,076	51,076
Capital Employed	1,66,101	1,72,444	1,72,979	2,21,884	2,85,684	3,37,396	3,81,363
Gross Block	95,368	1,05,127	1,17,618	1,31,807	1,47,692	1,54,667	1,61,830
Less: Accum. Deprn.	49,870	58,677	68,632	80,325	93,201	1,07,109	1,21,668
Net Fixed Assets	45,498	46,450	48,986	51,482	54,491	47,558	40,162
Capital WIP	8,475	8,948	5,957	3,555	6,952	6,826	6,763
Investments	9,000	5,169	10,747	13,840	15,462	15,462	15,462
Goodwill & Intangibles	31,306	40,534	41,566	47,323	58,657	58,657	58,657
Curr. Assets	1,22,236	1,26,861	1,29,656	1,69,796	2,41,949	3,04,360	3,65,580
Inventory	46,307	44,918	49,539	54,764	60,833	74,026	83,364
Account Receivables	42,619	44,807	46,920	54,971	66,041	74,347	82,188
Cash and Bank Balance	10,981	12,931	12,025	31,423	56,529	82,428	1,26,466
Others	22,328	24,205	21,171	28,638	58,547	73,558	73,563
Curr. Liability & Prov.	50,414	55,519	63,931	64,111	91,826	95,467	1,05,261
Account Payables	42,254	46,937	54,928	57,019	80,887	84,527	94,321
Provisions	8,160	8,581	9,003	7,093	10,939	10,939	10,939
Net Current Assets	71,822	71,342	65,725	1,05,685	1,50,123	2,08,893	2,60,320
Appl. of Funds	1,66,101	1,72,444	1,72,979	2,21,884	2,85,684	3,37,396	3,81,363

Financials and valuations

Ratios

Y/E March	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
EPS	19.0	8.6	41.3	71.5	116.5	109.8	113.7
Cash EPS	37.2	28.0	63.4	97.2	144.6	140.2	145.6
BV/Share	267.4	273.9	314.4	376.8	491.0	616.6	727.4
DPS	9.0	2.0	2.5	2.5	2.5	2.5	2.5
Payout (%)	-31.3	24.7	6.9	4.1	2.5	2.6	2.6
Valuation (x)							
P/E	125.0	277.7	57.6	33.3	20.4	21.7	20.9
Cash P/E	63.9	85.0	37.5	24.5	16.4	17.0	16.3
P/BV	8.9	8.7	7.6	6.3	4.8	3.9	3.3
EV/Sales	7.0	6.7	5.6	4.9	3.9	3.5	3.0
EV/EBITDA	56.0	63.7	30.7	21.1	13.4	13.5	12.4
Return Ratios (%)							
RoE	6.7	3.2	14.1	20.8	26.9	19.8	16.9
RoCE	8.6	3.5	12.6	17.7	21.7	17.0	15.3
RoIC	9.8	3.9	14.3	21.2	28.2	23.2	22.6
Working Capital Ratios							
Asset Turnover (x)	1.0	1.0	1.1	1.0	1.0	0.9	0.9
Fixed Asset Turnover (x)	3.6	3.6	4.2	4.5	5.3	6.0	7.6
Debtor (Days)	97	98	86	89	86	88	90
Creditor (Days)	129	136	163	158	208	193	190
Inventory (Days)	105	99	91	89	79	88	91
Leverage Ratio							
Current Ratio	2.4	2.3	2.0	2.6	2.6	3.2	3.5
Interest Cover Ratio	8.2	3.2	8.3	13.9	17.8	16.4	17.5
Debt/Equity (x)	0.3	0.3	0.1	0.1	0.0	-0.1	-0.2

Cash Flow Statement

Y/E March	FY22	FY23	FY24	FY25	FY26	FY27E	FY28E
PBT Before EO items	-13,722	7,165	24,223	40,150	68,726	78,419	81,600
Int./Dividends Recd.	468	2,422	2,280	1,589	2,159	3,230	3,400
Direct Taxes Paid	469	-2,432	-3,261	-9,060	-12,674	-10,724	-14,323
(Inc)/Dec in WC	-150	3,265	855	-14,105	6,337	-32,871	-7,389
CF from Operations	-12,936	10,420	24,098	18,573	64,548	38,055	63,287
Others	16,609	8,552	12,386	11,426	8,797	2	2
EO expense	0	0	0	0	0	0	0
CF from Op. incl EO Exp.	3,673	18,972	36,484	29,999	73,345	38,057	63,289
(inc)/dec in FA	-8,980	-14,611	-9,166	-16,531	-19,122	-6,850	-7,100
Free Cash Flow	-21,916	-4,191	14,931	2,042	45,426	31,205	56,187
(Pur)/Sale of Inv.	15,891	3,958	-5,374	-324	-23,804	0	0
Others	6,011	-2,214	-2,582	-24,864	4,280	0	0
CF from Investments	12,922	-12,868	-17,122	-41,719	-38,646	-6,850	-7,100
Change in Net Worth	161	19	146	399	165	8,680	210
Inc/(Dec) in Debt	-11,693	700	-17,331	24,277	2,790	-8,611	-7,000
Interest Paid	-1,240	-2,267	-2,829	-2,295	-3,615	-3,925	-3,820
Dividend Paid	-2,951	-1,825	-1,828	-3,653	-5,483	-1,329	-1,329
Others	0	0	0	-1,409	-4,893	-122	-212
CF from Fin. Activity	-15,723	-3,373	-21,842	17,319	-11,036	-5,307	-12,152
Inc/Dec of Cash	872	2,732	-2,481	5,599	23,663	25,899	44,037
Add: Beginning Balance	9,262	9,913	12,317	9,836	31,423	55,087	80,986
Cash/Cash Eq.	10,134	12,645	9,836	15,436	55,087	80,986	1,25,023
Forex/Bank	-221	-328	0	15,988	1,442	1,442	1,442
Closing Balance	9,913	12,317	9,836	31,423	56,529	82,428	1,26,466

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies).
MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).

6. MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
7. MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
8. MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
9. MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
10. MOFSL has not engaged in market making activity for the subject company.

 The associates of MOFSL may have:
 financial interest in the subject company
 actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.

received compensation/other benefits from the subject company in the past 12 months
 any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
 be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)

received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
 Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report
 Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263;

www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412. AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.